What question did this study set out to answer?

To determine the risk of overanticoagulation and dose requirements associated with CYP2C9*2 and CYP2C9*3 alleles in patients treated with acenocoumarol or phenprocoumon.

December 22, 2003Pharmacogenetics

The risk of overanticoagulation in patients with cytochrome P450 CYP2C92 or CYP2C93 alleles on acenocoumarol or phenprocoumon

View Full Paper

Ask AI

Bookmark

Authors

LVLoes E. VisserErasmus MC MVM. van VlietCodarts Rotterdam RSRon HN van SchaikErasmus MC

Discussion

Member takes

Implication

Cohort study reveals increased overanticoagulation risk on acenocoumarol but not phenprocoumon in CYP2C9 variant carriers, suggesting phenprocoumon is a safer alternative.

Key Points

To determine the risk of overanticoagulation and dose requirements associated with CYP2C9*2 and CYP2C9*3 alleles in patients treated with acenocoumarol or phenprocoumon.
Evaluated CYP2C9 genotypes in a cohort of 1124 patients from the Rotterdam Study treated with acenocoumarol or phenprocoumon.
Measured initial international normalized ratio (INR), occurrence of excessive anticoagulation (INR ≥ 6.0) over the first 6 weeks, and maintenance dose requirements.
Acenocoumarol-treated patients with CYP2C9*2 or CYP2C9*3 variants had a significantly higher mean initial INR, higher risk of INR ≥ 6.0, and required significantly lower maintenance doses compared to wild-type patients.
Phenprocoumon-treated patients showed no significant differences in initial INR, overanticoagulation risk, or maintenance dose requirements between variant and wild-type genotypes.

Cite This Study

Visser et al. (2003) studied this question.

synapsesocial.com/papers/6a126ce4f7bd4f5c7da64cf3 https://doi.org/10.1097/00008571-200401000-00003

View Full Paper

Ask AI

Bookmark

Implication

Cohort study reveals increased overanticoagulation risk on acenocoumarol but not phenprocoumon in CYP2C9 variant carriers, suggesting phenprocoumon is a safer alternative.

The risk of overanticoagulation in patients with cytochrome P450 CYP2C92 or CYP2C93 alleles on acenocoumarol or phenprocoumon

Discussion

Member takes

Implication

Key Points

Cite This Study

The risk of overanticoagulation in patients with cytochrome P450 CYP2C92 or CYP2C93 alleles on acenocoumarol or phenprocoumon

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon

Discussion

Member takes

Implication

Key Points

Cite This Study

The risk of overanticoagulation in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider

The risk of overanticoagulation in patients with cytochrome P450 CYP2C92 or CYP2C93 alleles on acenocoumarol or phenprocoumon

The risk of overanticoagulation in patients with cytochrome P450 CYP2C92 or CYP2C93 alleles on acenocoumarol or phenprocoumon